461 related articles for article (PubMed ID: 17504986)
1. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
2. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
3. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
4. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
5. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
7. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
8. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk.
De Ruyck K; Szaumkessel M; De Rudder I; Dehoorne A; Vral A; Claes K; Velghe A; Van Meerbeeck J; Thierens H
Mutat Res; 2007 Jul; 631(2):101-10. PubMed ID: 17531525
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
11. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
12. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer.
Brewster AM; Jorgensen TJ; Ruczinski I; Huang HY; Hoffman S; Thuita L; Newschaffer C; Lunn RM; Bell D; Helzlsouer KJ
Breast Cancer Res Treat; 2006 Jan; 95(1):73-80. PubMed ID: 16319991
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development.
Unal M; Güven M; Batar B; Ozaydin A; Sarici A; Devranoğlu K
Exp Eye Res; 2007 Sep; 85(3):328-34. PubMed ID: 17637462
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract][Full Text] [Related]
17. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
18. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer.
Popanda O; Schattenberg T; Phong CT; Butkiewicz D; Risch A; Edler L; Kayser K; Dienemann H; Schulz V; Drings P; Bartsch H; Schmezer P
Carcinogenesis; 2004 Dec; 25(12):2433-41. PubMed ID: 15333465
[TBL] [Abstract][Full Text] [Related]
19. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
[TBL] [Abstract][Full Text] [Related]
20. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
